MarketCap
Facebook
X
Telegram
BioVie ROA Ratio | BIVI
Annual ROA Ratio BioVie
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -81.36 | -127.42 | -143.16 | -129.68 | -2154.06 | -800.26 | -94.95 | -110.92 | -56.28 | -15.88 | -86.47 | -96.7 | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -15.88 | -2154.06 | -324.76 |
Quarterly ROA Ratio BioVie
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -103.0 | -91.88 | -76.22 | -84.93 | -77.51 | -58.54 | -83.93 | -117.7 | -123.31 | -103.76 | -137.0 | -111.61 | -157.17 | -112.1 | -241.87 | -235.46 | -219.21 | -198.85 | -250.26 | -272.87 | -278.6 | -273.96 | -239.52 | -207.61 | 99.99 | -25.93 | 379.7 | 248.85 | -49.76 | 84.84 | -197.06 | -80.47 | -89.11 | -105.75 | -132.04 | -156.49 | -148.55 | -133.85 | -97.71 | -55.26 | -60.81 | -67.49 | -72.84 | -79.26 | -83.32 | -81.28 | -83.95 | -81.36 | -68.89 | -62.41 | -44.7 | -11.58 | -12.0 | -3.46 | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 379.7 | -278.6 | -94.98 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Regeneron Pharmaceuticals
REGN
|
11.11 | $ 904.69 | 0.2 % | $ 94.6 B |  USA |
 |
Replimune Group
REPL
|
-94.44 | $ 21.67 | 8.24 % | $ 2.01 B | USA |
 |
DiaMedica Therapeutics
DMAC
|
-53.39 | $ 9.47 | 4.76 % | $ 445 M | USA |
 |
Royalty Pharma plc
RPRX
|
3.93 | $ 67.31 | -0.39 % | $ 28.9 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
-752.78 | - | - | $ 169 M | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
-0.04 | $ 111.51 | 6.18 % | $ 7.25 B | USA |
 |
Puma Biotechnology
PBYI
|
14.38 | $ 8.28 | -15.25 % | $ 414 M | USA |
 |
SIGA Technologies
SIGA
|
10.61 | $ 3.12 | 4.55 % | $ 223 M | USA |
 |
Sage Therapeutics
SAGE
|
-73.22 | - | - | $ 527 M | USA |
 |
Taro Pharmaceutical Industries Ltd.
TARO
|
1.19 | - | - | $ 1.62 B |  Israel |
 |
Sol-Gel Technologies Ltd.
SLGL
|
-20.48 | $ 61.62 | -2.21 % | $ 172 M | Israel |
 |
SELLAS Life Sciences Group
SLS
|
-34.29 | $ 8.41 | 6.73 % | $ 917 M | USA |
 |
Summit Therapeutics
SMMT
|
-143.72 | $ 16.34 | 15.15 % | $ 12.2 B |  Britain |
 |
Cabaletta Bio
CABA
|
-101.68 | $ 1.3 | 1.17 % | $ 131 M | USA |
 |
Syndax Pharmaceuticals
SNDX
|
-53.88 | $ 9.53 | 1.39 % | $ 826 M | USA |
 |
Sanofi
SNY
|
6.19 | $ 47.06 | 0.32 % | $ 57.4 B |  France |
 |
Forma Therapeutics Holdings
FMTX
|
-30.83 | - | - | $ 958 M | USA |
 |
Blueprint Medicines Corporation
BPMC
|
-5.69 | - | - | $ 8.14 B | USA |
 |
Horizon Therapeutics Public Limited Company
HZNP
|
5.72 | - | - | $ 26.6 B |  Irlanda |
 |
Sarepta Therapeutics
SRPT
|
-21.3 | $ 17.8 | 0.68 % | $ 1.78 B | USA |
 |
Paratek Pharmaceuticals
PRTK
|
-36.84 | - | - | $ 121 M | USA |
 |
China SXT Pharmaceuticals
SXTC
|
-17.85 | $ 2.84 | -3.07 % | $ 1.93 M |  China |
 |
Takeda Pharmaceutical Company Limited
TAK
|
0.76 | $ 21.02 | -0.92 % | $ 33.2 B |  Japan |
 |
Tarsus Pharmaceuticals
TARS
|
-11.74 | $ 68.11 | 0.87 % | $ 2.85 B | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
-179.56 | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Bio-Techne Corporation
TECH
|
7.03 | $ 72.78 | 0.17 % | $ 11.4 B | USA |
 |
Teva Pharmaceutical Industries Limited
TEVA
|
3.46 | $ 42.32 | 1.33 % | $ 48.5 B | Israel |
 |
RedHill Biopharma Ltd.
RDHL
|
-45.82 | $ 0.43 | 0.45 % | $ 5.3 B | Israel |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Unity Biotechnology
UBX
|
-69.01 | - | -33.41 % | $ 3.37 M | USA |
 |
iTeos Therapeutics
ITOS
|
-19.57 | - | - | $ 411 M | USA |
 |
Shattuck Labs
STTK
|
-53.62 | $ 4.59 | 2.78 % | $ 319 M | USA |
 |
Seelos Therapeutics
SEEL
|
-699.19 | - | -47.76 % | $ 6.27 M | USA |
 |
Evogene Ltd.
EVGN
|
-39.05 | $ 0.28 | -16.14 % | $ 2.2 M | Israel |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Protara Therapeutics
TARA
|
-27.4 | $ 2.33 | 9.15 % | $ 99.8 M | USA |
 |
Trevi Therapeutics
TRVI
|
-22.11 | $ 14.33 | 11.87 % | $ 1.93 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-55.34 | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Fennec Pharmaceuticals
FENC
|
-13807.03 | $ 9.79 | 4.26 % | $ 280 M | USA |
 |
Kiromic BioPharma
KRBP
|
-314.78 | - | 6.61 % | $ 3.08 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-183.81 | $ 3.92 | -2.24 % | $ 1.74 M | USA |
 |
Calithera Biosciences
CALA
|
-138.27 | - | -10.95 % | $ 876 K | USA |
 |
United Therapeutics Corporation
UTHR
|
16.94 | $ 562.14 | -0.63 % | $ 24.9 B | USA |
 |
Vericel Corporation
VCEL
|
3.39 | $ 54.56 | 5.36 % | $ 2.75 B | USA |
 |
Veracyte
VCYT
|
4.72 | $ 24.1 | 0.42 % | $ 1.89 B | USA |
|
Applied Molecular Transport
AMTI
|
-117.57 | - | - | $ 10.1 M | USA |
 |
Fulcrum Therapeutics
FULC
|
-20.44 | $ 3.72 | 0.95 % | $ 236 M | USA |
 |
Molecular Templates
MTEM
|
-22.96 | - | -23.43 % | $ 495 K | USA |
 |
Vanda Pharmaceuticals
VNDA
|
-45.1 | $ 3.82 | 6.27 % | $ 225 M | USA |
 |
Verrica Pharmaceuticals
VRCA
|
-37.98 | $ 3.22 | 4.21 % | $ 34.3 M | USA |